Testing MT027 for brain and spinal cord metastases
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new drug called MT027 for people whose solid tumors (like lung or breast cancer) have spread to the brain, spinal cord, or their protective lining. The goal is to see if it is safe and helps shrink or control these metastases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a solid tumor (like lung, breast, or colon cancer) that has spread to the brain, spinal cord, or the lining of the brain
- Your doctor expects you to live at least 3 more months
- You are able to do most daily activities on your own (Karnofsky score of 70 or higher)
- You do not have severe heart, lung, liver, or kidney problems
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to choose treatment for people with brain tumors that have not responded to standard therapies. Your tumor sample is analyzed in the lab to find which drugs might work best for you, and then you receive a personalized treatment plan.
This trial tests a new drug called MT027 for people with advanced cancer that has spread to the lining around the lungs (pleura) and caused fluid buildup. The drug targets a marker on cancer cells called B7-H3. It may help control the fluid and the cancer.
This trial tests a new drug, NBQ72S, for people with breast cancer that has spread to the lining of the brain or spinal cord (leptomeningeal metastasis). It aims to see if the drug is safe and helpful for these patients.
This trial tests a new drug called JSKN027 for people with advanced solid tumors (cancers that have spread) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors.
This trial tests a new drug, MT027, for people with high-grade glioma (a type of brain tumor) that has come back or continued to grow after standard treatment. The drug targets a protein called B7-H3 found on tumor cells. The goal is to see if it can help shrink tumors or slow the disease.
This trial studies people with solid tumors that have spread to the brain (including the brain lining) to help researchers learn what works and how best to treat it. You may be asked for blood/tissue samples and a procedure to collect spinal fluid when brain metastases are diagnosed.
Hear when a new Brain (Nervous System) Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.